

GUIDANCE FRAMEWORK FOR TESTING **GENETICALLY MODIFIED MOSQUITOES**

Second edition

World Health Organization For research on diseases of poverty





GUIDANCE FRAMEWORK FOR TESTING **GENETICALLY MODIFIED MOSQUITOES** Second edition Guidance framework for testing genetically modified mosquitoes, second edition

ISBN 978-92-4-002523-3 (electronic version) ISBN 978-92-4-002524-0 (print version)

© World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases, 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO, including TDR, endorses any specific organization, products or services. The use of the WHO and TDR logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO) or by the Special Programme for Research and Training in Tropical Diseases (TDR). WHO, including TDR is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Guidance framework for testing genetically modified mosquitoes, second edition. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO, including TDR, concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO, including TDR, in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO, including TDR, to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO, including TDR, be liable for damages arising from its use.

Layout and cover design: M Booth Health

Contents

Forewo	rd	v
Acknow	/ledgements	ix
Abbrev	iations	xi
Glossar	у	xiii
Executi	ve summary	xix
1. Introc	luction	1
1.1	GMM strategies	3
1.2	2 GMM approaches	4
1.3	Characteristics of GMMs	11
1.4	Potential utility of GMMs	12
1.5	6 GMM testing pathways	13
1.6	Decision-making	17
1.7	Critical pathway for GMMs	
2. Effica	acy evaluation	25
2.1	Efficacy end points of GMMs	
2.2	2 Trial planning considerations	29
2.3	Entomological efficacy studies	
2.4	Epidemiological trial design	37
2.5	Implementation and post-implementation surveillance	
2.6	5 Efficacy measurement at different testing phases	40
2.7	Co-development and capacity strengthening	
3. Safet	y evaluation	50
3. Safet 3.1	y evaluation. Risk analysis	50 51
3. Safet 3.1 3.2	y evaluation Risk analysis ? Types of risk assessment	50 51 55
3. Safet 3.1 3.2 3.3	y evaluation Risk analysis ? Types of risk assessment 9 Site characteristics	50 51 55 56
3. Safet 3.1 3.2 3.3 3.4	y evaluation Risk analysis 7 Types of risk assessment 8 Site characteristics 4 Appropriate comparators	50 51 55 56 56
 3. Safet 3.1 3.2 3.3 3.4 3.5 	y evaluation Risk analysis 7 Types of risk assessment 8 Site characteristics 4 Appropriate comparators	50 51 55 56 57

	3.7	Target safety profile	63
	3.8	Risk assessment and management at different testing phases	64
	3.9	Safety review	
	3.10	Impact assessment	
	3.11	Co-development and capacity strengthening	80
4. Et	hica	l considerations	87
	4.1	Role of ethics and engagement in science and technology	
	4.2	Ethics issues	
	4.3	A strategy for ethical engagement	100
	4.4	A tailored, early, sustained engagement process	104
	4.5	Engagement at different testing phases	108
	4.6	Capacity strengthening for ethical engagement	113
5. Re	egula	atory frameworks	119
	5.1	The purpose of regulations	120
	5.1 5.2	The purpose of regulations Local oversight bodies	120 121
!	5.1 5.2 5.3	The purpose of regulations Local oversight bodies Relevant regulation and regulatory precedents	
	5.1 5.2 5.3 5.4	The purpose of regulations Local oversight bodies Relevant regulation and regulatory precedents Other guidance and recommendations	
	5.1 5.2 5.3 5.4 5.5	The purpose of regulations Local oversight bodies Relevant regulation and regulatory precedents Other guidance and recommendations Regulation at different testing phases	
!	5.1 5.2 5.3 5.4 5.5 5.6	The purpose of regulations Local oversight bodies Relevant regulation and regulatory precedents Other guidance and recommendations Regulation at different testing phases Additional considerations pertinent to GMMs regulation	
Anne	5.1 5.2 5.3 5.4 5.5 5.6 5. 6	The purpose of regulations Local oversight bodies Relevant regulation and regulatory precedents Other guidance and recommendations Regulation at different testing phases Additional considerations pertinent to GMMs regulation Additional information on relevant international organizations,	
Anne treat	5.1 5.2 5.3 5.4 5.5 5.6 ex 1. ies a	The purpose of regulations Local oversight bodies Relevant regulation and regulatory precedents Other guidance and recommendations Regulation at different testing phases Additional considerations pertinent to GMMs regulation Additional information on relevant international organizations, and covenants	
Anne treat Anne	5.1 5.2 5.3 5.4 5.5 5.6 •••••••••••••••••••••••••••••••	The purpose of regulations Local oversight bodies Relevant regulation and regulatory precedents Other guidance and recommendations Regulation at different testing phases Additional considerations pertinent to GMMs regulation Additional information on relevant international organizations, and covenants Examples of national legislation and regulation pertaining to GMMs	
Anne treat Anne	5.1 5.2 5.3 5.4 5.5 5.6 ex 1. ies a	The purpose of regulations Local oversight bodies Relevant regulation and regulatory precedents Other guidance and recommendations Regulation at different testing phases Additional considerations pertinent to GMMs regulation Additional information on relevant international organizations, and covenants Examples of national legislation and regulation pertaining to GMMs	

Foreword



Dr Soumya Swaminathan Chief Scientist & WHO Special Coordinator for TDR World Health Organization

Vector-borne diseases are endemic in more than 100 countries and affect approximately half of the world's population (1). Many types of arthropods may serve as disease vectors, but this guidance focuses particularly on mosquitoes. Mosquitoes transmit several diseases of major global public health importance, including malaria and dengue fever (1). In fact, mosquitoes have been called the deadliest animal on earth (2).

Malaria is still considered the world's most important parasitic infectious disease. Intensive deployment of currently available malaria control tools over the past two decades has greatly reduced malaria incidence (3). However, this overall trend has slowed in recent years, and even reversed in some parts of Africa (4, 5). The *Global technical strategy for malaria 2016–2030* (6) sets a target of reducing global malaria incidence and mortality rates by at least 90% by 2030 (compared to 2015 levels). Yet, it is widely acknowledged that eliminating malaria in all countries, especially those with a high disease burden, will likely require new tools that are not available today (6–8). Therefore, investing in research and development of innovative vector control tools has been identified as a priority (9).

An estimated 2.5 billion people live in areas where dengue viruses can be transmitted. Dengue has been called the most important mosquito-borne viral disease with epidemic potential in the world, citing a 30-fold increase in the global incidence of dengue over the past 50 years, and recognizing that the human and economic costs are staggering. The number of cases reported increased from 2.2 million in 2010 to over 3.34 million in 2016 (*10*). Outbreaks and epidemics of other viruses carried by the same mosquitoes that transmit dengue have occurred in Africa, the Americas, Asia and the Pacific (*1, 11*).

Attacking mosquito vectors is one of the most effective ways to reduce the transmission of these diseases in endemic areas (12). Application of mosquito population reduction methods was central to the successful elimination of malaria transmission in Italy and the United States of America in the early 20th century (13) and, transiently, of dengue in the Americas in the early 1960s (14). Vector-targeted approaches remain a mainstay of current disease control practices. However, given the

Guidance framework for testing genetically modified mosquitoes, second edition

magnitude of ongoing malaria and dengue incidence, current efforts clearly are insufficient to meet the need. Moreover, dependence on a limited number of insecticides for vector control increases the risk that mosquitoes will develop resistance (15), exacerbating the problem. Insecticide resistance is being reported in over three quarters of countries with ongoing malaria transmission, and such resistance affects all major vector species and classes of insecticide (7). Resistance to all four classes of insecticide has also been reported in *Aedes* arbovirus vectors in the Americas, Asia and Africa (16).

In considering the potential of new technologies to address the unmet needs of mosquito control, it is necessary to evaluate the benefits and risks in the context of the current situation. The potential public health benefit of practical and effective new tools to reduce or even eliminate diseases such as malaria and dengue is clear and widely recognized (17). Both the risks incurred by testing new and unproven control strategies and the risks to human health and the environment posed by maintaining the status quo, which include ongoing health (morbidity and mortality), environmental (use of broad-spectrum insecticides) and economic (18–20) impacts, should be taken into account in decision-making.

For more than two decades, scientists have been working to harness the promise of molecular biology to develop genetically modified mosquitoes (GMMs) for use as public health tools to prevent the transmission of these diseases. The introduction of molecular biology techniques represents the next step in a progression that builds on the widespread success of programmes employing release of radiation-sterilized insects to control the Mediterranean fruit fly (Medfly) and other insect pests affecting plants and animals, a process known as the sterile insect technique (SIT) (21). Radiation- and chemo-sterilization, sometimes in combination with biological sterilization methods, have been applied to mosquitoes (22-24). However, genetic modification technologies offer additional options for specificity and durability of effect, as well as adaptability to different disease transmission conditions. Advances in the development of GMMs have raised hopes for the availability of new, potent and cost-effective tools to aid in the fight against malaria, dengue and other mosquito-borne pathogens. Data on which to base the evaluation of GMMs' protective potential can only be collected through testing, including testing under the natural conditions in which the technology would be utilized. Without the ability to conduct careful and rigorous testing, no new technology of any kind can be brought to fruition for the public good.

Some of these genetic technologies are now advancing to field testing. Field testing of GMMs began with releases of non-replicating male mosquitoes (which do not bite) (25–27). The first field release of non-sterile, self-limiting GMMs was announced in 2019 (28). To date, no gene drive-modified

预览已结束,完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5 23882